Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin after hospital discharge for COVID-19
2020-001319-26Phase 3Active
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoints: Primary composite endpoint and Primary objective composite endpoint. Started May 2020; status: active.
02
Drugs
rosuvastatin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001319-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001319-26.